Drug Trial Radar · NCT07669506
A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jun 17, 2025
Primary completion
Apr 25, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Natureceuticals Sdn BhdIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine whether Nuvastatic™ can reduce cancer-related fatigue and improve quality of life in adult female patients with breast cancer undergoing standard chemotherapy. The main questions it aims to answer are: Does Nuvastatic™ reduce cancer-related fatigue as measured by change in the Brief Fatigue Inventory (BFI) from baseline to end of treatment? Does Nuvastatic™ improve quality of life, safety outcomes, and clinical parameters compared with placebo during chemotherapy? Researchers will compare patients receiving Nuvastatic™ plus standard chemotherapy with patients receiving placebo plus standard chemotherapy to see if Nuvastatic™ leads to greater reductions in fatigue, improved quality of life, and acceptable safety while undergoing treatment. Participants will: * Receive Nuvastatic™ or matching placebo as a 1000 mg effervescent sachet taken three times daily after meals for three chemotherapy cycles * Continue their standard-of-care chemotherapy as prescribed by their treating physician * Complete fatigue and quality-of-life questionnaires (BFI, SF-36, EORTC QLQ-C30) * Undergo routine clinical assessments, laboratory tests, ECGs, and safety monitoring * Undergo CT imaging for tumor response assessment according to RECIST 1.1
Conditions
- Breast Neoplasms
- Fatigue
- Quality of Life
- Chemotherapy, Adjuvant
Interventions
Nuvastatic ™Drug
Greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet
PlaceboDrug
greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Brief Fatigue Inventory (BFI) scoreTime frame: At baseline until end of treatment at 12 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Department of Medical Oncology (In Charge - Oncology Unit), Govt. Medical College & Govt. General Hospital,
Srikakulam, Andhra Pradesh, India
Hanji Cancer Centre
Belagavi, Karnataka, India
K.R. Hospital, Mysore Medical College & Research Institute
Mysuru, Karnataka, India
Onco-Life Cancer Centre
Satara, Maharashtra, India
Onco-Life Cancer Centre, Pvt. Ltd (Talegaon General Hospital)
Talegaon Dābhāde, Maharashtra, India
Siddharth Gupta Memorial Cancer Hospital (A Unit of Acharya Vinoba Bhave Rural Hospital)
Wardha, Maharashtra, India
Avicenna Hospital
Lucknow, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.